Pacira jumped into M&A chatter after investor DOMA Perpetual urged a full sale, arguing the biotech could fetch $66/share. Activist pressure follows solid EXPAREL growth but weak stock performance. ...
Nektar Therapeutics rises after reports of Eli Lilly’s buyout interest and strong Phase IIb results for REZPEG. With FDA Fast Track status and solid cash reserves, investor optimism builds. ...